Your Cart is Empty
Parts 1 and 2 of this series covered the science of peptides and the practical decisions around using them.
This final article is structured around the most frequently asked questions about peptides in skincare, as well as ingestible collagen peptides.
Peptides are short chains of amino acids, the same building blocks that make up larger proteins like collagen and elastin.
What makes them interesting in skincare is their size. Full proteins are too large to penetrate the skin. Certain peptides are small enough to reach the dermis, where they act as biological messengers, sending signals that tell cells to produce, protect, or repair.
The reason they keep coming up in conversations about changing midlife skin is that the biological changes of perimenopause and menopause affect exactly the systems peptides help to address.
Declining oestrogen slows fibroblast activity, weakens the barrier, and destabilises melanocyte regulation.
Peptides can step into each of these gaps directly to help support changing skin.
Yes, and this is one of the most important reasons they matter for skin in hormonal transition.
Declining oestrogen thins the skin and compromises the barrier, and what used to be manageable with a strong retinoid or high-percentage acid can become persistent redness or irritation. Many of us abandon the actives that were working for us because our skin can no longer tolerate the routine of stronger actives like acids and retinoids.
Peptides carry no irritation risk. There is no adjustment period, no photosensitivity, no peeling. They work with the skin’s existing biology rather than accelerating or forcing it, which means consistent daily use is realistic even for skin that has become sensitised.
If your skin has become reactive during hormonal transition, peptides are the category most likely to support real change without triggering the sensitivity that prevents you from using the product consistently.
Eight to twelve weeks of consistent daily use to start seeing a real difference is the honest answer - but then there is also the case of ongoing maintenance.
Barrier peptides can improve skin feel and hydration within the first few weeks. But the structural changes peptides are best known for, improvements in firmness, visible reduction of fine lines, changes in skin density, take longer because the process being stimulated is biological.
Signal peptides work by prompting fibroblasts to produce more collagen. Collagen synthesis takes time. Products that promise dramatic transformation in a week are describing something other than how this mechanism actually works.
8-12 weeks of daily use is the minimum honest evaluation period.
Think of it like strength training. The mechanism is real and the results are measurable. But they require consistent effort over time, not a single session.
Peptides are one of the most compatible active categories in skincare. They do not disrupt pH the way acids do and do not compete with most other ingredients for the same receptor pathways.
With vitamin C:complementary. Vitamin C protects against free radical damage that degrades existing collagen. Signal peptides stimulate new collagen production. They work on the same concern from different angles.
With retinoids: genuinely complementary. They stimulate collagen through different mechanisms. A morning-peptide, evening-retinoid pattern works well, as does alternating nights.
With niacinamide: an excellent combination. Niacinamide supports the barrier, reduces inflammation, and has its own brightening effect through a different pathway to brightening peptides.
With hyaluronic acid: a natural pairing. HA improves the hydration of the vehicle in which peptides are delivered, supporting penetration and overall skin feel.
Peptides and Retinoids work through completely different mechanisms, which is why they can be so useful together.
Retinoids work by binding to retinoic acid receptors and accelerating cellular renewal. They increase the rate at which old cells shed and new ones are produced, reducing wrinkles, correcting photodamage, and addressing acne. The evidence base is exceptional and spans decades.
Peptides do not accelerate cell turnover. They send direct signals to fibroblasts and other skin cells, telling them to produce more collagen, reinforce the barrier, regulate pigmentation, or slow the nerve signals causing muscle micro-contractions.
For midlife skin, the practical implication is significant. Many women find declining oestrogen makes retinoids increasingly difficult to tolerate. The adjustment period that was once brief becomes ongoing irritation, and a product that causes persistent irritation gets abandoned. An abandoned retinoid produces no results at all.
For skin that still tolerates retinoids: use both, they are complementary. For skin that no longer tolerates retinoids: a well-formulated peptide routine can address many of the same concerns without the sensitivity that prevents consistent use.
Related mechanism, different application, and most usefully thought of as complementary rather than interchangeable.
Hydrolysed collagen supplements are broken down into small peptide fragments during digestion and distributed systemically.
Several well-designed clinical trials, including the Proksch studies, show real improvements in skin hydration, elasticity, and density at doses of 2.5 to 10 grams per day over eight to twelve weeks.
The key difference is that you cannot direct where systemic support goes. It benefits skin throughout the whole body, which is genuinely useful for overall health, but you cannot concentrate it on a specific concern.
Topical peptides work locally. Applied to the face, they target fibroblasts in the dermis of that area. Applied to the neck, they work there. The support lands precisely where you put it.
A supplement builds a better systemic collagen environment throughout the body. A topical peptide delivers targeted signals to specific sites of visible concern. Neither replaces the other.
The skin changes of perimenopause and menopause are real, measurable, and biologically specific. They are not imagination and they are not simply the gradual effects of time.
Oestrogen has receptor sites in skin tissue. It actively supports fibroblast activity, regulates barrier lipid synthesis, modulates melanocyte activity, and supports the skin’s repair response.
When it declines, all of these processes shift simultaneously. Research estimates skin loses approximately 30% of its collagen in the first five years following menopause. Barrier lipid content decreases. Melanocyte regulation becomes less stable. The repair response slows.
Will peptides help peri and menopause skin?
Yes, it can - if formulated well and used correctly and consistently. Signal peptides address declining fibroblast activity. Barrier peptides address lipid reduction and dehydration. Brightening peptides address melanocyte instability. Enzyme inhibitor peptides slow the increased collagen-degrading enzyme activity that accompanies oestrogen decline. The match between peptide types and the specific changes of skin changing during peri and menopause (oestrogen depletion amongst other changes) is a biological alignment, not a marketing coincidence.
Your skin in midlife hasn't stopped responding - it is experiencing a profound hormonal shift and needs different support. That is what peptides can provide.
Yes, and this is one of the areas where peptides can offer something traditional brightening ingredients do not.
Traditional brighteners like kojic acid typically target a single enzyme (tyrosinase) in the melanin production pathway. When melanocyte activity is driven by hormonal instability, addressing one enzyme is often insufficient.
Advanced brightening peptides, particularly Tetrapeptide-30 (Tego Pep 4, developed by Evonik), intervene at multiple points in the melanin production and distribution cascade simultaneously. Clinical data demonstrates it outperforms kojic acid in reducing hyperpigmentation across different skin tones, with no irritation.
Two important caveats: brightening peptides address the skin-level mechanism but cannot address the hormonal driver (ie. melasma).
And SPF every morning is non-negotiable. UV is the most potent additional stimulus for melanocyte activity, and any brightening work done without sun protection is working against itself.
Yes, and this deserves far more space in the peri and menopause conversation than it currently receives.
Hair thinning, increased shedding, and reduced density are amongst the most distressing aspects of hormonal transition. There are two distinct mechanisms at work. Oestrogen supports the anagen (active growth) phase of the hair cycle, and as it declines more follicles shift prematurely into the telogen (resting and shedding) phase. Separately, the shift in the oestrogen-to-androgen ratio during menopause can trigger androgenic-pattern thinning.
Biotinoyl Tripeptide-1 (Procapil) strengthens follicle anchoring to the dermal papilla, improves scalp microcirculation, and shows DHT-inhibiting activity. Relevant for both types of menopause-related thinning.
GHK-Cu (Copper Peptide) has evidence for extending the anagen phase and improving follicle activity, alongside its skin benefits.
Acetyl Tetrapeptide-3 targets the extracellular matrix of the scalp dermis, improving the structural anchoring of the follicle.
Note: no topical product reverses significant hair loss. What these peptides represent is some of the better-evidenced options in a category full of overpromising.
Used consistently as part of a targeted scalp routine, they may be worth including.
This phrase originated largely with a peptide ingredient called Argireline (Acetyl Hexapeptide-8), and was actually used by the ingredient’s own developer, Lipotec, who describe it as having a “Botulinum Toxin-like mechanism of action.” So the comparison came from the ingredient supplier as part of their marketing strategy.
The mechanism is real: Argireline works by interfering with the neurotransmitter signals that cause repeated facial muscle contractions, softening the appearance of dynamic expression lines on the forehead and around the eyes.
But what the phrase does not tell you is that a topical peptide applied to the surface of skin and a neurotoxin injected directly into a muscle are operating at completely different depths, with entirely different levels of effect and duration.
Argireline has solid clinical evidence for what it does. What it does is genuinely useful.
It is simply not botox in a bottle, and framing it that way sets an expectation no topical ingredient can meet.
We would rather tell you what peptides can actually do for skin navigating changes , because what they can actually can already be helpful for skin.
Peptide flooding covers two distinct practices, and understanding the difference matters for both how you build your routine and how you evaluate products.
Consumer-side "peptide flooding"is layering multiple peptide products in sequence in the belief that more contact time and more variety compounds results.
Peptides cross the skin barrier using specific transporter proteins, and those transporters have a capacity ceiling. There is a biological absorption limit regardless of how much is applied. Thoughtful layering of different peptide types targeting different mechanisms makes sense.
For example, three serums all containing the same Matrixyl and Argireline combination applied in sequence does not add meaningful value beyond the first application.
Brand-side "peptide-flooding" is the more significant issue from a consumer perspective. It describes the practice of loading a formulation with as many different peptides as possible and using that number as a primary marketing claim.
The economics are worth understanding clearly.
The peptides with genuine clinical evidence, the proprietary named peptides from suppliers such as Sederma, Evonik, Lubrizol and Lipotec, are expensive to synthesise. When a product lists 10-15 peptides at a price point that cannot mathematically support all of them at meaningful concentrations, some may well be present at token levels. They may be on the label, but they may not be in the product in any functionally useful sense.
For example, Numbuzin markets a peptide product with around 50 peptides - but given what these ingredients actually cost to manufacture, is unlikely to support meaningful concentrations of multiple named, clinically evidenced actives.
On the other end of the scale, Medik8’s Advanced Collagen Serum markets a figure describing its total peptide presence (around 30% peptide complex).
The figure is not fabricated, but the question it does not answer is: what proportion of that total does each individual peptide represent, and is each present at its minimum effective concentration? A formulation in which many peptides share a collective total, each therefore necessarily present below its individually active level, is not the same as a formulation in which a smaller number of peptides are each present at their clinical minimum. The percentage sounds impressive. What it communicates about efficacy may be misleading.
Five peptides, each named, each with clinical evidence, each at an active concentration, will consistently outperform twenty at trace levels. The number on the label is not the question. The concentration of each is.
Six questions will tell you almost everything you need to know.
Q1: Peptides are biological messengers that signal skin cells to produce, protect, and repair. For hormonal skin, the mechanism aligns directly with the biology of oestrogen decline.
Q2: Peptides are safe for sensitive and reactive skin with no irritation risk, adjustment period, or photosensitivity. Consistent daily use is achievable.
Q3: Allow eight to twelve weeks of daily use for visible structural results. Consistency matters more than cost.
Q4: Peptides combine well with vitamin C, niacinamide, hyaluronic acid, and retinoids. Use acids in a separate step.
Q5: Peptides and retinoids work through different mechanisms and complement each other. For skin that can no longer tolerate retinoids, peptides offer a consistent alternative.
Q6: Collagen supplements and topical peptides are complementary, not interchangeable: systemic support versus local, targeted signalling.
Q7: The skin changes of hormonal transition are real and biological. Each peptide type addresses a specific consequence of oestrogen decline.
Q8: Brightening peptides, particularly Tetrapeptide-30 (Tego Pep 4), address hormonal melasma through multi-pathway melanin regulation. SPF is non-negotiable alongside any brightening routine.
Q9: Biotinoyl Tripeptide-1 (Procapil), GHK-Cu, and Acetyl Tetrapeptide-3 have meaningful clinical evidence for menopause-related hair thinning.
Q10: The ‘botox in a bottle’ claim overstates what topical peptides can do. Argireline has real evidence for softening expression lines. It is not botox.
Q11: Peptide flooding describes both over-layering at home and brand-side overloading of formulas at sub-active concentrations. Five named, active peptides outperform fifty at trace levels.
Q12: Evaluate any peptide product by named ingredients, INCI position, price logic, supplier traceability, brand explanation quality, and formulation stability.
This is the final article in the Beauty by Ané Peptides in Skincare series.
Part 1 covered the science of peptides in skincare and the six different types.
Part 2 covered the practical decisions around retinoids, supplements, hair, and investment value.
Part 3 of our Estrogen-Depleted Skin Series tackles a frequently asked question: does HRT actually help your skin?
In this piece, I share my own decade-long journey navigating conflicting HRT advice, a hysterectomy with no follow-up care, and the experience of being caught between doctors who disagreed.
I also break down the science: what estrogen was doing in your skin, why women lose approximately 30% of their collagen in the first five years after menopause, what the clinical evidence says about HRT and skin, the truth about topical estrogen face creams (including the unregulated ones you can buy on Amazon), and what to do if HRT is not part of your picture.
